Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
DECODE Study Group, on behalf of the European Diabetes Epidemiology Study Group Correspondence to: Dr Knut Borch-Johnsen, Steno
Diabetes Centre, Niels Steensens Vej 2, DK 2820 Gentofte, Denmark
kbjo{at}novo.dk
Objective: To evaluate the impact of the revised
diagnostic criteria for diabetes mellitus adopted by the American
Diabetes Association on prevalence of diabetes and on classification of
patients. For epidemiological purposes the American criteria use a
fasting plasma glucose concentration
7.0 mmol/l in contrast with
the current World Health Organisation criteria of 2 hour glucose
concentration
11.1 mmol/l.
Design: Data were collected from 13 populations and
three occupational based studies from eight European countries. All
studies used a 75 g oral glucose tolerance test to measure fasting and
2 hour glucose concentrations.
Subjects: 17 881 men; 8309 women; age range 17-92 years.
Main outcome measures: Classification of diabetes
according to both sets of criteria.
Results: The application of the American criteria on
European populations induced changes in prevalence of diabetes ranging
from a reduction of 4.0% to an increase of 13.2%. A total of 1517 previously undiagnosed individuals had diabetes according to either the
WHO or the American criteria. Among 1044 with diabetes according to
American criteria, only 45% had 2 hour values fulfilling the WHO
criteria. The risk of disagreement of classification decreased with
increasing body mass index (P<0.00001) and increasing age (P<0.0001);
the impact of sex was not significant (P=0.08).
Conclusions: This shift in strategy from using 2 hour
to fasting plasma glucose will cause an increase in the prevalence of
diabetes in some European populations. A high degree of disagreement in
the classification was observed between the two recommendations.
Prospective data are needed to evaluate whether the WHO or the American
criteria best identify individuals at risk of developing microvascular
complications and cardiovascular disease. Wider implementation of
revised diagnostic criteria should await prospective data.
Key messages
© BMJ 1998
Read all Rapid Responses